Timber Pharmaceuticals Inc is a company that upholds strong values and a clear corporate philosophy. It strives to prioritize the well-being of patients and the development of innovative healthcare solutions. With a commitment to improving lives, Timber Pharmaceuticals Inc focuses on delivering high-quality products and services. The company believes in investing in research and development to address unmet medical needs and enhance patient care. By valuing integrity, dedication, and collaboration, Timber Pharmaceuticals Inc aims to make a meaningful impact on the healthcare industry.

Timber Pharmaceuticals Inc is primarily present in the United States of America.

Timber Pharmaceuticals Inc has achieved several significant milestones. Recently, the company successfully completed a Phase 2b clinical trial for its lead product candidate, TMB-001, for the treatment of moderate to severe atopic dermatitis. These positive results demonstrated the potential efficacy and safety of TMB-001. Additionally, Timber Pharmaceuticals Inc has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for TMB-001, which recognizes the urgent need for innovative treatment options in the dermatology field. The company's dedication to advancing novel therapies has positioned Timber Pharmaceuticals Inc as a key player in the pharmaceutical industry.

Timber Pharmaceuticals Inc, a leading pharmaceutical company, has a rich history and a strong background in the healthcare industry. Founded in [insert year], the company has been dedicated to developing innovative and effective therapies for various medical conditions. Timber Pharmaceuticals Inc has established itself as a reliable player in the market, continually striving to improve patient care and outcomes. Throughout the years, the company has garnered recognition for its commitment to research and development, forging strategic partnerships, and delivering breakthrough treatments. With a focus on delivering value to its shareholders and improving global healthcare, Timber Pharmaceuticals Inc remains a trusted name in the pharmaceutical sector.

The main competitors of Timber Pharmaceuticals Inc in the market include companies such as Dermira Inc, Novartis International AG, and Johnson & Johnson. These companies operate in the pharmaceutical industry and offer products and services similar to Timber Pharmaceuticals Inc. However, Timber Pharmaceuticals Inc distinguishes itself through its unique product offerings and innovative approaches in addressing various dermatological conditions.

Timber Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Timber Pharmaceuticals Inc. focuses on developing and commercializing dermatology products. The company aims to address unmet medical needs in various dermatological conditions, including rare and orphan diseases. Timber Pharmaceuticals utilizes its expertise in clinical development, regulatory affairs, and product commercialization to bring innovative therapies to market. The company collaborates with key stakeholders, such as patients, physicians, and healthcare providers, to enhance patient care and provide effective treatment options. With its commitment to dermatology, Timber Pharmaceuticals Inc. strives to improve the quality of life for individuals suffering from dermatological disorders.

Raportul Timber Pharmaceuticals preț/beneficiu este -0,00.

Raportul Timber Pharmaceuticals preț/vânzări este 0.

Scorul de calitate AlleAktien pentru Timber Pharmaceuticals este 4/10.

Cifra de afaceri nu poate fi calculată în prezent pentru Timber Pharmaceuticals.

Profitul așteptată Timber Pharmaceuticals este -620,33 milioane USD.

Timber Pharmaceuticals Inc. is a company based in New York City that is engaged in the development of medications and therapy options. The company aims to provide innovative solutions for a variety of diseases that currently have unsatisfactory treatment options. Timber Pharmaceuticals has developed a wide portfolio of products and pipelines focusing on different medical areas, including dermatology, oncology, and ophthalmology. The company's main focus is dermatology and it has developed some unique developments in this field. One example is Tamixofen, a topical medication developed by Timber Pharmaceuticals to alleviate the effects of eczema on the skin. The company also offers therapies for rare diseases, such as TMB-001 for the treatment of Xeroderma Pigmentosum. Timber Pharmaceuticals collaborates closely with leading medical experts and research institutions to continuously improve and develop its products and pipelines. In addition to its wide range of products, the company employs a strong marketing strategy, including collaborations with well-known companies in the healthcare industry. Overall, Timber Pharmaceuticals' business model is defined by innovation and a focus on providing groundbreaking innovations in the medical and pharmaceutical industries.

Timber Pharmaceuticals distribuie un dividend de 0 USD în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru Timber Pharmaceuticals sau compania nu distribuie dividende.

Codul ISIN pentru Timber Pharmaceuticals este US8870801094.

Codul WKN al Timber Pharmaceuticals este A2P4ZX.

Ticker-ul pentru Timber Pharmaceuticals este TMBR.

În ultimele 12 luni, Timber Pharmaceuticals a plătit un dividend în valoare de . Aceasta corespunde unei randamente a dividendului de aproximativ . Pentru următoarele 12 luni, Timber Pharmaceuticals va plăti probabil un dividend de 0 USD.

Randamentul dividendelor pentru Timber Pharmaceuticals este în prezent de .

Timber Pharmaceuticals plătește un dividend trimestrial. Acesta este distribuit în lunile .

Timber Pharmaceuticals a plătit dividende în fiecare an, în ultimii 0 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0 USD. Acest lucru corespunde unei randamente a dividendelor de 0 %.

Timber Pharmaceuticals este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Timber Pharmaceuticals de la 21.09.2024 în valoare de 0 USD, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 21.09.2024.

Ultima plată a dividendului a fost efectuată la 21.09.2024.

În anul 2023, Timber Pharmaceuticals a distribuit 0 USD sub formă de dividende.

Dividendele de la Timber Pharmaceuticals sunt distribuite în USD.